Gdalevich M, Grotto I, Mandel Y, Mimouni D, Shemer J, Ashkenazi I
Medical Corps, Israel Defense Force.
Epidemiol Infect. 1998 Oct;121(2):477-9. doi: 10.1017/s0950268898001198.
This study sought to determine whether the decline in prevalence of hepatitis A virus (HAV) antibodies detected in Israel in 1977, 1984, and 1987 has continued. The anti-HAV antibody prevalence of a systematic sample of 578 male and female recruits inducted into the Israel Defence Force in 1996 was 38.4%. The reduction in antibody prevalence from 1977 (64%) was highly significant (P < 0.001). There was a smaller decrease rate in recruits of European, North American, Australian and South African origin than from elsewhere. A 'strategy' that uses active immunization against hepatitis A (inactivated vaccine, instead of gamma globulin) should be considered, particularly in high risk groups such as field units during military service.
本研究旨在确定1977年、1984年和1987年在以色列检测到的甲型肝炎病毒（HAV）抗体流行率的下降趋势是否仍在持续。1996年被征召入以色列国防军的578名男女新兵的系统样本中，抗-HAV抗体流行率为38.4%。与1977年（64%）相比，抗体流行率的降低非常显著（P<0.001）。欧洲、北美、澳大利亚和南非裔新兵的下降率低于其他地区。应考虑采用针对甲型肝炎的主动免疫策略（使用灭活疫苗，而非丙种球蛋白），特别是在诸如服兵役期间的野战部队等高风险群体中。
